Decreased signs of inflammation and no erosive progression on ultrasonography at 6 and 12 months in patients with rheumatoid arthritis in adalimumab and methotrexate combination therapy.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt